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Buprenorphine is a unique pharmaceutical in the management of chronic pain and opioid use 
disorder (OUD).  Buprenorphine is a semisynthetic partial opioid agonist at the mu opioid 
receptor and an antagonist of the kappa opioid.  Buprenorphine Maintenance Therapy (BMT) is 
utilized for the long-term treatment of patients with OUD. The attraction to this methadone 
alternative is increased safety profile, more convenient patient access to the drug, as well as 
increase of ease for the provider.  The particular formula used in the US, Suboxone, has 
properties to discourage intravenous injection to prevent abuse and prevent negative secondary 
effects of intravascular injections in general.  Buprenorphine, a partial agonist, has an affinity 
higher than that of a full agonist at the mu receptor. It has lower efficacy, slow offset, as well as 
a ceiling effect, making surgical analgesia difficult to control for those on a maintenance therapy. 
In the clinical setting, many opinions and theories have been discussed in the approach to 
managing perioperative pain for a patient on BMT.  Use of buprenorphine is increasing, 
“nevertheless, there is limited and conflicting information in the literature pertaining to the 
optimal management of buprenorphine-stabilized patients presenting for surgery”. (Huang, 
Katznelson, Perrot, & Clark, 2014).  In a search through the literature, there has been varying 
protocols and theories presented intertwined with case studies.  The goal of this paper is to 
review buprenorphine and to discuss the current literature on the perioperative management for 
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Buprenorphine and the Anesthesia Considerations: a Literature Review 
Reckitt and Colman Pharmaceuticals synthesized buprenorphine in the late 1960s as a 
semisynthetic opiate for the treatment of chronic pain, in particular, cancer pain.  In the late 
1970s, it was proposed at a treatment for opiate dependence or abuse.  It was the Drug Addiction 
Treatment Act of 2000 (DATA 2000) that allowed a breakthrough of prescriptive authority for 
buprenorphine.  DATA 2000 gave physicians legality in prescribing opioids for the treatment of 
opioid addiction.  In 2002, the FDA approved a particular formulation of buprenorphine, 
Suboxone, for the treatment of opioid-dependent persons.  Nationally there are over 16,700 
providers registered to prescribe Suboxone.  In Maine, there are 120 registered providers with 
new physicians being added weekly. According to DATA 2000, each registered physician 
prescribing Suboxone is limited to 30 patients in the first year of prescribing, up to 100 patients 
thereafter.  (SAMHSA, 2015).  Buprenorphine in the formulation of Suboxone is in increasing 
demand nationally. Its presence in the patient population is presenting the need for evidence 
based practice in the perioperative setting.      
    The pharmaceutical properties of buprenorphine create a unique challenge for the anesthesia 
provider in the management of pain.  Many of the articles and case studies state the lack of 
consensus on surgical pain management in patients on BMT, thus presenting a topic with need 
for further exploration.  “To date, there have been no randomized controlled studies published 
involving the effects of different pain control modalities applied to patients maintained on 
buprenorphine... evidence supporting recommendations is currently based on a number of case 
reports and the shared experience of clinicians”.  (Bryson, 2014). The next few paragraphs will 
discuss the properties, the pharmacokinetics and mechanism of action of buprenorphine; 
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following will be the presentation of case studies, review of current literature and discussion 
points. 
    Buprenorphine is a partial agonist of the mu receptor and potent kappa receptor antagonist.  
Mu receptor stimulation produces supraspinal analgesia, euphoria, respiratory depression, 
bradycardia, and dependence. Kappa stimulation produces spinal analgesia, sedation, miosis, and 
dysphoria; these latter effects are antagonized with buprenorphine. (Nagelhout, 2010).  “In some 
patients, kappa agonists produce dysphoria. Buprenorphine’s absence of kappa agonist effects 
may explain why dysphoria and other unpleasant mood effects are rarely produced in 
buprenorphine users.”  (Wesson & Smith, 2010).  Typically synthetic opioids are designed to be 
highly selective for specific receptors.  Most clinically used opioids are selective for the mu 
receptor alone.   
    The receptor theory, as discussed in Barash (2009), states that drugs have two independent 
characteristics at receptor sites, affinity and efficacy.  Affinity is the ability to bind to a receptor 
to produce a stable complex.  Efficacy is a dose effect curve resulting from the drug-receptor 
combination.  A partial agonist has a dose-effect ceiling that is lower than that of a full agonist.  
Barash (2009) goes on to state, “even at a very large doses the efficacy, or maximum effect 
achieved by the partial agonist will be less than the maximum possible effect of a full agonist”.  
Buprenorphine is described as “having a high affinity for the mu receptor, 1000-fold higher than 
morphine, with an extremely slow dissociation from the receptor”.  (Bryson, Lipson, & Gevirtz, 
2010).  Although it binds tightly, it only partially activates the receptor, reducing the efficacy.  
This satisfies the classification of a partial agonist.  Its affinity for the mu receptor is greater than 
that of naloxone as well as other mu agonists and it will displace a full agonist from the mu 
receptor.  As a result of being a partial agonist with high mu receptor affinity, slow dissociation, 
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and long duration of action, buprenorphine is an effective agent for treatment of OUD and 
addiction.  (Vadivelu, Mitra, Kaye, & Urman, 2014).   Buprenorphine has an increased safety 
profile because of the partial agonism compared to methadone, a full agonist.  Less respiratory 
depression is noted as well as a decrease in the euphoric high associated with a full agonist.  This 
is attributed to the ceiling effect of respiratory depression and euphoria.    
    As mentioned earlier, in 2002, a particular formulation of buprenorphine was released into the 
market, Suboxone.  Suboxone is a 4:1 blend of buprenorphine and naloxone, released as a 
sublingual formula.  The amount of naloxone in the combination drug is considered not 
bioavailable if the medication is taken as prescribed, sublingually.  The naloxone only becomes 
active if the medication is snorted or injected intravascular.  If abused, the naloxone will 
precipitate withdrawal symptoms.  If Suboxone is dissolved and injected by someone who is 
physically dependent on a full opiate agonist, the naloxone will displace the full agonist, (not the 
partial agonist) precipitating withdrawal.  This addition of naloxone essentially decreases the 
abuse potential of Suboxone, making it not ideal for abuse by those that are dependent on a full 
agonist.  The naloxone is only present as a deterrent for abuse, not to reduce the mu receptor 
activation as some providers mistakenly believe.  (Wesson & Smith, 2010). The patient 
population enrolled in BMT for OUD in the US is primarily taking the Suboxone formula.    
    The following is a brief overview of the pharmacokinetics and dosing.  Buprenorphine as 
supplied in the treatment for OUD is a sublingual formula with a bioavailability of 30%-50%, the 
PO formula has a decreased bioavailability of 3-14% due to is extensive first pass elimination.  It 
is metabolized in the liver by cytochrome P450 3A4 enzymes leaving norbuprenorphine as one 
of its metabolites. Norbuprenorphine as considered to have some opioid activity but its potency 
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and significance is unclear (Roberts & Meyer-Witting, 2010).  Metabolites are excreted primarily 
in the bile and eliminated in the feces.  
    Buprenorphine is both lipophilic and highly protein bound.  It is distributed to adipose tissue 
and slowly redistributed to plasma, extending the half-life.  The half-life is route and dose 
dependent.  Higher doses are utilized in BMT whereas significantly lower doses are used for 
chronic pain.  In general, high dose buprenorphine has a half-life of 20-70 hours, low dose 
therapy has an approximate half-life of 2-6 hours.  (Roberts & Meyer-Witting, 2005).   
According to the published work of Wesson and Smith (2010), the plasma half life of sublingual 
buprenorphine in opioid naïve healthy males was approximately 26 hours.  In their analysis, 
considerable individual differences were apparent with computed half-lives ranging from 6-96 
hours.  The time from ingestion to maximum plasma level ranged from 0.5 to three hours.   The 
literature clearly indicates a large range in the half-life of buprenorphine. 
    As alluded to earlier, there is a variety in dosing related to therapeutic goals.  A low dose 
analgesic regimen for those with chronic pain or cancer pain would typically be a range of 2-
4mg/24hr divided in to doses to be administered every 6 hours.  A much higher dosing regimen 
is utilized in BMT with a reported 24-hour maximum of 32mg.  “Beyond 32mg/24hr, a ceiling 
effect in terms of analgesia occurs due to the partial agonist effect of buprenorphine at the opioid 
receptor.” (Huang et al, 2014). Obviously dosing is tailored to patient specific needs.   
     Buprenorphine is appearing more often in patient’s medical regimens and due to its 
pharmaceutical properties it can be difficult to manage these patients in the perioperative setting.  
“The same properties that make buprenorphine advantageous for management of addiction and 
chronic pain present a challenge to anesthesiologists.”  (Chern, Isserman, Chen, Ashburn, and & 
Liu, 2012)  A search through the literature was completed via Medline, Lexicomp, Cochrane 
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database, UpToDate, and Google Scholar.  What was found was a series of case studies and 
publish recommendations as well as institution based protocols.   What was not found was 
systematic reviews nor controlled studies in the search for anesthesia management for patients 
taking chronic buprenorphine.   The articles found continue to reiterate the need for further 
controlled studies. The next few pages will present current case studies as well as proposed 
protocols.  
Literature Review 
     In 2010 Harrington & Zaydfudim presented a case study involving a young male stabilized on 
BMT who sustained multisystem trauma in a motorcycle accident.  His acute pain was difficult 
to manage due to his BMT.  The patient presented on some form of buprenorphine.  Trauma 
evaluation revealed: right frontal lobe brain contusion, grade IV liver laceration, grade III spleen 
laceration, right renal hematoma, right rib fractures of 5,6,7, and a right olecranon fracture.  
During the initial hospitalization the patient was agitated and required high doses of narcotics.  
Agitation became managed with haloperidol and lorazepam; pain was treated with high dose full 
agonist opiates.  By post injury day 3 (PID 3), the patient’s analgesic needs began to decline.  
Additional history revealed the patient was actively on a BMT and on PID 4, his regimen was 
restarted with the aim of obtaining better pain management.  Tapering of narcotics did not 
happen, and on PID 6 the patient’s requirements increased to 50mg of morphine, 37 mg 
haloperidol, 8mg of lorazepam and 17mg of midazolam.  The hospitals medical-psychiatry 
service evaluated the patient and determined the diagnosis of delirium was attributed to the TBI.  
The buprenorphine was also thought to contribute to insufficient analgesia leading to further 
agitation.  The buprenorphine was discontinued resulting in a marked reduction in narcotic 
demand.  The patient’s mental status and related agitation improved rapidly.  The patient was 
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discharged on daily a dose of 120mg of SR oxycodone and counseled of future re-evaluation for 
his BMT. 
     The authors note that the pain management improvement on PID 3 is consisted with the 
wearing off of the approximate 72-hour buprenorphine induced blockade of hydromorphone 
effects.  In adding buprenorphine into the regimen on PID 4, pain requirements for full agonists 
increased, demonstrating the displacement of full agonists by the partial agonist.  The follow up 
response by the authors is discouraging the continuation of buprenorphine during an acute pain 
syndrome.  In reinstating the BMT, it may perpetuate the problem.  “In addition, attempt to treat 
acute pain with incrementally greater doses of buprenorphine may precipitate frank opiate 
withdrawal due to kappa receptor antagonism that predominates at higher doses”  (Harrington & 
Zaydfudim, 2010).  
     In 2012, the American Journal of Emergency Medicine published a case report that 
demonstrated buprenorphine inhibiting remifentanil.  A 22-year-old male presented to the ER 
with a work related injury to his right forearm.  He was in severe pain, ashen, diaphoretic, and 
writhing on the stretcher.  His right wrist was deformed, no palpable pulse, and fingers were 
dusky.  X-ray revealed a severe distal radial and ulnar fracture. The patient denied any other 
significant medical history.  Morphine 10mg was injected SQ while IV access was obtained but 
resulted in no pain relief.  A remifentanil infusion was initiated at 0.7mcg/kg/min with no 
apparent beneficial effect at 8 minutes into the infusion.  The patient continued to writhe in pain 
and 1mg of lorazepam was administered.  A bolus of remifentanil 1mcg/kg was administered 
with no effect.   That particular order was given verbally to which the patient responded, 
“fentanyl won’t work on me, I’m taking Suboxone”.  Apparently he was prescribed suboxone for 
chronic back pain.  The remifentanil infusion was stopped and a Bier block was successfully 
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administered.  The patient had complete anesthesia to the affected limb within 5 minutes.  The 
patient calmed down, ashen appearance reversed and was no longer diaphoretic.  The fracture 
was reduced and the patient was discharged with a prescription for Percocet.  
     The authors of this particular report conclude that patients in need of emergent pain relief 
taking suboxone should be given some form of non-opioid pain management.  Recommendations 
included ketamine, propofol, nitrous oxide, and etomidate.  Regional anesthesia highly 
recommended as well as NSAIDS, acetaminophen and tramadol.  (Gilmore, Saccheti, & Cortese, 
2012). 
     The Journal of Anesthesia and Clinical Research published a more complicated case study in 
2012 involving a 37-year-old patient with a Type 1 Chiari malformation who was receiving 
buprenorphine, 8mg TID, for chronic pain management.  This patient underwent two separate 
but similar gynecologic procedures 6 months apart.  The patient had chronic pelvic pain and was 
scheduled for removal of vaginal mesh.  She had developed erosion and pain from the mesh and 
already had prior office visits for trimming of the mesh.  
     At the most recent vaginal mesh trimming, at an outside hospital, the patient was instructed to 
continue her buprenorphine up to the day of surgery, but reported that this resulted in severe pain 
in the post-operative period.  She requested a pre-operative consultation for perioperative pain 
management before her upcoming gynecologic procedure at the author’s facility.  She was 
instructed to stop her buprenorphine 5 days prior to surgery and start hydromorphone PO, 4mg 
Q4-6hours.  Upon the morning of surgery the patient reported adequate pain control on the 
hydromorphone and experienced no difficulty in transitioning from the buprenorphine to the full 
agonist.  In the pre-operative area, a fentanyl challenge was started. The patient was given 
100mcg of fentanyl IV and was given additional boluses of 50mcg of fentanyl every 1-2 minutes, 
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up to 400mcg.  The patient remained alert and conversational and was then transported to the OR 
with the fentanyl challenge still being administered.  She had received a total of 1000mcg of 
fentanyl before induction and was still conversational.  Induction included 80mg of lidocaine IV, 
200mg propofol IV, and 100mg succinylcholine IV.  Tracheal intubation was performed and GA 
was maintained with sevoflurane, an additional 100mcg of fentanyl IV was given as well as 
30mg toradol IV.   
    Upon emergence the patient complained of severe, unbearable right hip pain after being taken 
out of lithotomy.  The patient was re-sedated with propofol and fentanyl and an urgent 
orthopedic consult was completed and a dislocated hip was ruled out.  Again, 100mcg boluses of 
fentanyl were administered ever 1-2 minutes in the PACU, again adding up to 1000mcg of 
fentanyl.  The anesthesia team was consulted for additional pain management in the PACU.  She 
continued to report the pain as a 7-8/10.  Hydromorphone 8.5mg IV was given and a PCA with 
the same opioid was set up with a basal rate of 2mg/hour and a demand dose of 0.6 mg every 10 
minutes, toradol 30mg every 6 hours was also included in the regimen.  After 24 hours, she was 
transitioned back to her pre-op dose of hydromorphone, 4mg every 3 hours, with acceptable pain 
control.  She was able to ambulate, void and tolerate a regular diet.  She was then discharged on 
a limited amount of hydromorphone and was instructed to follow up with her buprenorphine 
prescriber to transition back to buprenorphine. This study is interesting in that the authors were 
aiming to create a case study of comparing two similar procedures with 2 different 
buprenorphine regimens.  The post-op extreme hip pain created an entirely different scenario 
with an unpredicted outcome. 
     In the discussion section of the case report, the authors state there is no consensus in the 
literature as to how to best manage acute pain in patients taking buprenorphine.  They do 
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however present and discuss 3 options in this setting.  The first option is to continue the baseline 
regimen and supplement with additional buprenorphine.  This is considered ideal because in the 
patient that is avoiding re-exposure to full agonist opioids.  The concern is that the ceiling effect 
will prevent sufficient analgesia.  The second option is to continue the pre-op buprenorphine and 
if pain control is not sufficient after adding more buprenorphine, traditional full agonist opioids 
should be added to supplement.  The caveat is that very large doses of opioids will be required 
and sedation and respiratory depression can be very concerning at those high doses, thus 
requiring higher levels of close monitoring.   The third option is to convert the buprenorphine to 
a full agonist preoperatively with resuming of prior buprenorphine following the acute 
perioperative period.  While there is no antagonist effect to overcome, large doses of opioids 
may be required as described in this particular case due to significant opioid tolerance.  The last 
recommendation by this author group is the encouraged use of multimodal pain control with 
administration of local anesthesia, regional anesthesia, and NSAIDS.  The challenge of this case 
was that there was no wound or incision to infiltrate and a regional technique was not considered 
given the theoretical risk of exacerbating the symptoms of a Type 1 Chiari malformation.   
(Chern, Isserman, Chen, Ashburn & Liu, 2012). 
     The Canadian Journal of Anesthesia published an interesting case report in 2014 involving a 
patient on suboxone for chronic pain.  The patient was a 47-year-old female with a history of 
chronic pain that presented to the authors facility for a Clagett window closure procedure. She 
had a bronchopleural fistula following a right upper lobectomy for pulmonary aspergillosis.  Her 
pain management was complicated by nociceptive and neuropathic pain in both her chest and 
right arm that had persisted for several months.  Several regimens had been attempted including 
oxycodone up to 260mg per day, fentanyl patch (100mcg/hour), Cymbalta, cyclobenzaprine, 
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NSAIDS, tricyclic antidepressants, and a transcutaneous electrical nerve stimulation unit.  These 
were all discontinued due to lack of benefit or due to side effects.  The patient’s pain was 
primarily chest wall pain at the site of the Clagett window involving a burning and aching 
sensation that often radiated to her right shoulder and jaw. She reported her baseline pain to be a 
7/10 with frequent episodes of 10/10 pain.  Her chronic pain had caused her functional status to 
deteriorate and she required assistance with her activities of daily life.   
    At the time of her closure surgery, her pain regimen included suboxone 16mg bid, gabapentin 
1,200mg tid, venlafaxine 225mg daily, and nabilone 1mg bid.  A thoracic epidural was placed at 
T6 and a general anesthetic used.  Intraoperatively she received ketamine 45mg IV and 
hydromorphone 1.6mg IV.  The procedure was 2.5 hours and she was extubated in the OR and 
brought to the PACU without any issues.  On post op day 1 (POD 1) she continued to receive a 
thoracic epidural infusion of 0.2% ropivicaine at 5ml/hr and also had a hydromorphone PCA 
with bolus doses of 0.6-0.8mg every 5 min.  In the immediate post op period, her pain was well 
controlled with the above therapy.  She did however start to develop new right shoulder pain 
with radiation to her hand and numbness to her fingers. The neurology team was consulted and 
with their findings, it was determined the patient had a right brachial plexus stretch injury.   
     By POD 5, the thoracic epidural began to fail, and she began experiencing profound pain at 
the surgical site requiring 15-20mg/24hr of hydromorphone via her PCA.  She began to 
experience sharp and burning pain, rating it a 7-8/10 with episodes of 10/10 again.  The epidural 
catheter was removed on POD 7, followed by increasingly difficult to manage pain, using 30-40 
mg/24hr of hydromorphone via her PCA.  The authors make a note here to state that at this time, 
she was still continuing to receive her usual home analgesics including her Suboxone.  On POD 
11, in addition to her PCA doses, the patient began taking Hydromorph Contin 12mg bid; shortly 
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thereafter it was increased to 24mg bid with little benefit. By this time, her PCA doses of 
hydromorphone were increased to 50-70mg/24hr for nearly persistent 10/10 pain.  The 
possibility of interference from her maintenance suboxone was considered at this point. The 
decision to reduce her Suboxone from 16mg bid to once daily was made and her Hydromorph 
Contin was discontinued.  According to the article, immediately after the suboxone dose was 
reduced, her pain control markedly improved.  She was reporting pain back down to a 7-8/10 
from 10/10 in the first couple days post the suboxone taper. Her PCA requirements were also 
decreased back down to 15-25mg/24hr.  Within 10 days of reducing her suboxone, the PCA was 
discontinued and she was transitioned to PO hydromorphone. Again, her suboxone was reduced 
from 16mg once daily to 8 mg once daily. The patient was finally discharged on POD 41 and her 
regimen consisted of Hydromorph Contin 9mg tid, baclofen 10mg tid, gabapentin 1,200mg tid, 
venlafaxine 225mg once daily, and nabilone 1mg bid.  At the time of discharge, her pain was a 
3-5/10, which as the authors emphasize, was lower than her preoperative values.   She was 
evaluated 3 weeks post discharge and was offered to transition back to Suboxone.  She declined.  
She was more satisfied with the current regimen and due to nausea and anorexia she experienced 
with the Suboxone, she refrained from getting back on it.  
     In discussing this particular patient’s course, the authors state that the refractory nature of her 
pain was likely due to the saturation of opioid receptors by buprenorphine, which limited the 
effect of additional opioids administered.  The receptor affinity of buprenorphine is sufficiently 
strong enough to displace the full opioid agonists, minimizing their effect.  The authors conclude 
that overpowering buprenorphine occupied receptors is very challenging. They agree with other 
literature that recommends considering taking a patient off buprenorphine between 3-7 days 
preoperatively; meanwhile converting the patient to a full agonist for pain treatment as well as to 
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avoid opioid withdrawal.  The pitfall being that post-operatively these patients are typically 
reintroduced to buprenorphine at some point and consequentially may have difficult to manage 
pain.  Of note, this patient was on the suboxone formulation, not straight buprenorphine.  As 
described earlier, suboxone is a 4:1 ratio with naloxone.  Whereas the sublingual dose of 
naloxone is not considered significant enough to cause systemic effect, the authors contemplated 
that with her high dose of buprenorphine at 32mg/day, her naloxone dose was 8mg/day.  
According to literature, sublingual doses >4mg have been shown to precipitate withdrawal 
symptoms.  This suggests that higher doses of sublingual naloxone can produce antagonist 
effects at the opioid receptor.  This larger amount of absorbed naloxone may have contributed to 
the ineffectiveness of IV hydromorphone in this particular case.   
   Again these authors state the limited recommendations in the literature regarding perioperative 
management of patients on buprenorphine.  This is the first case report of a thoracic-specific 
report involving a patient stabilized on buprenorphine.  This was a complicated case in that the 
patient had such high and difficult to manage pain to start with, plus she sustained a brachial 
plexus injury, and the frequency of this type of procedure is not common.  In closing statements, 
the authors state the need for further research and more evidence based protocols and guidelines.  
(Huang, Katznelson, Perrot & Clark, 2014).  
     In the search through the literature, a few recommendations were described in how to manage 
perioperative pain in patients stabilized on BMT.  In an article published in Anesthesiology 
News, four options are described.  First, maintain BMT as prescribed and add short acting 
opioids, titrating to effect.  Be prepared that the patient will require significantly higher doses of 
full agonist opioids to achieve an expected effect.  The second option is to divide the patients 
BMT dose into 3 times daily dose to take advantage of its analgesic properties.  This approach is 
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recommended if the anticipated procedure is not likely to be too invasive or typically not very 
painful. Third option is to stop the BMT and administer full opioid agonists while assessing for 
withdrawal.  The authors again stress that 5 days may be required to free up the opioid receptors 
from the last dose of buprenorphine.  The final fourth option is to convert to methadone 30-
40mg/day.  This is the recommended dose to deter withdrawal symptoms.  It is noted that 
because methadone cannot be prescribed for withdrawal apart from a methadone clinic, the dose 
needs to be prescribed for treating pain, not managing withdrawal.  (Vaghari, Baratta, & Gandhi, 
2013). 
     Bryson (2014) published an article discussing the perioperative management of patients on 
various pharmaceuticals for opioid addiction.  He states again that there are no randomized 
controlled studies published involving the effects of pain control modalities applied to patients 
on BMT; current guidelines are based on case reports and shared experience of clinicians.  
Bryson’s work involved reviewing case studies and current guidelines based on collective 
experience.  His overall recommendation is to stop buprenorphine therapy before surgery with a 
gradual tapper down over a period of two weeks, with a final stop 3 days before surgery.   In the 
event that time does not permit, the provider should have the patient hard stop 3 days prior to 
surgery omitting the taper.  If withdrawal precipitates, convert to methadone or another full 
agonist opioid before surgery.   
     If the patient is to be maintained on buprenorphine, supplement with short acting opioids and 
titrate to achieve reasonable pain control understanding that effective doses will be much higher, 
putting the patient at risk for respiratory depression.  An alternate choice is to maintain the 
patient on their daily dose of buprenorphine, but divide the dose and administer it every 6-8 
hours to achieve the peak analgesic mechanism of the buprenorphine. This method is considered 
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appropriate for only mild-moderate anticipated pain.  This author does emphasize that if the 
patient is at high risk for relapse, the plan should be to replace the BMT with methadone before 
surgery.  Other general recommendations are to maximize regional techniques, utilize indwelling 
peripheral nerve catheters, NSAIDS, and low-dose ketamine infusions.  (Bryson, 2014). 
     In  2006 Annals of Internal Medicine published an article with recommendations for treating 
acute pain in patients receiving BMT or methadone therapy.  Their recommendations were very 
similar to the Bryson (2014) recommendations including that the ideal approach is to taper 
buprenorphine gradually.  In an inpatient setting, the recommendation is to convert to methadone 
30-40mg/day to abate withdrawal.  Because methadone binds less tightly to the mu receptor, 
additional opioid analgesics will be effective as expected allowing for adequate titration as 
needed.  When the acute pain is resolved, the full agonists should be discontinued as well as the 
methadone.  The patient should resume their previous BMT once the early signs of mild opioid 
withdrawal manifest.  This particular article emphasized collaboration with the primary 
prescriber of the buprenorphine to best manage the individual patient. (Alford, Compton, & 
Samset, 2006). 
     Wasson & Beirne (2013) published their work related to buprenorphine therapy and it’s 
challenge in the outpatient setting for oral and maxillofacial surgery.  A typical outpatient deep 
sedation regimen for oral and maxillofacial surgery combines benzodiazepines with opioids such 
as fentanyl or remifentanil.  This technique achieves the synergistic effect for the ideal depth of 
sedation as well as analgesia.  Administration of opioids to patients taking buprenorphine will 
not yield these benefits.  Their recommendation is to anticipate opioids to not be effective and 
instead adjunct the benzodiazepines with propofol.  A ketamine infusion maybe useful, but in 
this setting excessive salivation must be addressed and the prolonged recovery time is not ideal, 
Buprenorphine and the Anesthesia Considerations 
 
17 
thus propofol is superior.  Another recommendation is to utilize dexmedetomidine, the selective 
alpha2 agonist.  Because of its long loading dose timing and prolonged recovery dose, it may not 
be ideal in the office setting, again suggesting the superiority of propofol. 
     Post-operative pain management strategies are also described in this article.  Similar to other 
pieces mentioned above, an ideal approach is to collaborate with the buprenorphine prescriber, 
stop the buprenorphine and transition to a full agonist, recognizing the period to free the mu 
receptors may take up to 60 hours.  To transition back to buprenorphine, the patient should have 
an opioid free period of 12-24 hours.  Again, another approach is to maintain the patient on their 
buprenorphine daily dose, but divide it in to doses to be given every 6-8 hours to rely on the 
analgesic property alone.  This approach is considered appropriate if the anticipated pain is mild 
to moderate. In patients expected to have ongoing need for pain management, replacing 
buprenorphine with methadone provides the flexibility of supplementing full opioid agonists on 
top of the methadone without fear of a ceiling effect in analgesic therapy.  In the office setting of 
maxillofacial surgery use of local anesthetics is the normal approach, leaving an indwelling 
nerve catheter is not logistical.  Multimodal therapy is recommended in this setting with use of 
preoperative and postoperative NSAIDS, acetaminophen, as well as corticosteroids. The 
corticosteroids have been shown to decrease pain, edema, and trismus associated with oral 
surgery.  The authors note that the benefits of corticosteroids have not been found for all types of 
surgery or in all instances.  (Wasson & Beirne, 2013). 
    In 2014, Best Practice & Research Clinical Anesthesiology published an article discussing 
perioperative analgesia in the OUD patient.  This author group does describe the approach of 
discontinueing the buprenorphine 72 hours prior to surgery as well as transitioning to a full 
agonist preoperatively.  Also, they suggest the option of staying on the maintenance 
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buprenorphine and supplementing additional sublingual buprenorphine post-operatively, stating 
that buprenorphine is intrinsically a strong analgesic.  In this article buprenorphine is described 
as having a potency of 30 times greater than that of morphine. Yet the analgesic half-life is 
shorter than the half-life of the drug, thus supplementing additional doses more frequently is an 
adequate approach.  This article does not however address the ceiling effect of 32mg/24hr and 
the limitations in dosing additional buprenorphine in patients maintained on high does BMT.   
Multimodal therapy is encouraged with low dose ketamine infusions intraperatively (60-
120mcg/kg/hr), as well regional/local techniques.  Anti-inflammatory medications, anti-
depressants, and anti-convulsants are useful adjuncts to opioids as well.  (Vadivelu, Mitra, Kaye, 
& Urman, 2014). 
     As the search through the literature continued, an actual protocol was found, as opposed to 
guidelines and recommendations.  The Acute Pain Services (APS) at the University of Michigan 
created a protocol (Figure 1 &2) with the assistance of physicians specializing in Suboxone 
management.  It is a detailed protocol with considerations for elective surgery and 
urgent/emergent surgery, as well as considerations for levels of anticipated pain.  The protocol is 
prefaced by encouraging collaboration with APS as well as the patient’s primary suboxone 
prescriber in order to tailor an individual plan.  Prolonged admissions should be anticipated for 
pain management, as post-operative pain will likely still be difficult to manage.  Pathways on the 
protocol included maintaining BMT if appropriate as well as withholding it for 5 days to 
transition to full agonists, all similar to the previous works presented but with further detail and 
direction as protocols typically function.  Multimodal approaches are described and strongly 
recommended as well as continued collaboration with the buprenorphine prescriber.   (University 
of Michigan Health Systems). 
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     In 2014 a published pain physician,  from Boston Medical Center countered the University of 
Michigan’s protocol stating that the “5 day rule” of ceasing buprenorphine 5 days out is based on 
theoretical concern of pharmacological principles and has never been evaluated.  His concern 
with the protocol is that it risks causing a disruption in the patient’s recovery from opioid 
addiction by stopping buprenorphine during a high anxiety preoperative period.  According to 
Alford’s work, patients should take the last dose of buprenorphine on the morning of the day 
prior to surgery, hold buprenorphine of the day of surgery, and give an extended release opioid 
pre-operatively. Post-operatively, continue to hold the buprenorphine and give supplemental 
opioids such as fentanyl, while maintaining an extended release opioid.  In approximately one 
week post operatively, the patient should be seen by their buprenorphine provider to be 
considered to restart their BMT.  In his publication, Alford debates the certainty of the ceiling 
effect of buprenorphine stating there is no published data indicating an analgesic ceiling in 
humans.  Alford’s work, endorsed by Boston Medical Center really stands to confirm that there 
is not yet a consensus in the literature or among providers in the management of patients 
stabilized on BMT in the perioperative setting.  (Alford, 2014). 
 
Discussion 
     This literature review presents a variety of recommendations as well as actual case studies 
involving perioperative approaches and experiences to managing patients on buprenorphine 
whether its use is for OUD or chronic pain.  Over and over again, it is discussed that there is a 
lack of consensus, lack of randomized controlled studies, therefore a lack of systematic reviews 
for this topic.  The articles found are based on pharmacologic principles, case studies, and 
various suggestions based on clinical experiences.    
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     It is clear that buprenorphine, in the form of Suboxone, is increasing in presence in the patient 
population as it’s safety profile increases ease of access, ease of providers, and contains 
appropriate deterrent for abuse.  Pharmacologically, it is a unique drug in its potent yet partial 
agonizing effects of the mu receptor.  The half-life of buprenorphine varies in the 20-72 hour 
range with an affinity higher than that of any full agonist.  When analyzing the properties of the 
drug, it is clear that managing acute pain and surgical pain in this population is difficult.  What is 
not clear is the perfect formula for optimizing pain management in this population.  That being 
said, the literature presented offers consistencies in recommendations, providing options for the 
provider to consider for each patient. 
     Consistencies are observed in that multi-modal approaches should be utilized. Many authors 
recommend ketamine, an NMDA antagonist, as an opioid alternative peri-operatively.  Also 
consistent is the recommendation of infiltration of local anesthesia, promoting indwelling 
peripheral nerve catheters when possible, as well as use of non-opioid adjuncts such as NSAIDS, 
acetaminophen, Celebrex, Cox 2 inhibitors, and gabapentin.  Consulting a facility’s pain 
specialist and team collaboration is consistently recommended. 
    Overall the significant weaknesses of the article guidelines are that they are generalized and 
not tailored to specific surgeries, complexities of surgery, co-existing diseases, age populations, 
or individual addiction complexities.  In an ideal setting, there is excellent communication 
between a surgeon, a primary care physician, and the BMT physician to establish the perfect 
plan.  In the real world setting of a busy surgical setting, not every patient enrolled in a BMT 
program gets evaluated days in advance to create an optimized plan.  Communication with the 
patient is paramount as well setting realistic pain management goals. 
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     Ultimately, the anesthesia provider ought to remain informed in multimodal therapies, remain 
alert for additional literature to surface as well as continue to practice the art and science of 
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